Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large‐scale pharmacovigilance analysis
Qian Guo, Jian Gao, Hui Guo, Jun Xie, Jingmin Cheng
Topics & Concepts
IpilimumabNivolumabMedicinePharmacovigilanceAdverse Event Reporting SystemAdverse effectInternal medicineDurvalumabPembrolizumabOncologyAtezolizumabMedDRAPure red cell aplasiaImmunotherapyCancerAnemiaCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesPharmacovigilance and Adverse Drug Reactions